Literature DB >> 24732049

Confusing Relative Risk with Absolute Risk Is Associated with More Enthusiastic Beliefs about the Value of Cancer Screening.

Tanner J Caverly1, Allan V Prochazka2,3, Ingrid A Binswanger2,4, Jean S Kutner2, Daniel D Matlock2.   

Abstract

BACKGROUND: Reviews of how data are presented in medical literature document that the benefit from an intervention is often exaggerated relative to the harm (e.g., relative risk for benefit and absolute risk for harm). Such mismatched presentations may create unwarranted enthusiasm, especially among those who misinterpret the statistics presented. The objective was to determine whether misinterpretation of risk data predicts enthusiasm for cancer screening.
METHODS: The authors administered a survey with 14 items assessing beliefs about cancer screening and 6 items measuring data interpretation ability. Multiple linear regression was used to evaluate the association between data interpretation and enthusiasm for cancer screening, with adjustment for gender and year graduated from medical school.
RESULTS: Eighty-eight of 139 physicians at a state-wide professional meeting returned completed surveys (63% response rate). Lower data interpretation scores were associated with higher enthusiasm for cancer screening scores (P = 0.004) in the adjusted primary analysis. Confusing relative risk with absolute risk appeared to drive the overall association.
CONCLUSIONS: Biased presentations of risk data could affect general beliefs about the value of cancer screening, especially among physicians who uncritically accept mismatched presentations of data.
© The Author(s) 2014.

Entities:  

Keywords:  medical education; numeracy; physicians; risk communication; statistics

Mesh:

Year:  2014        PMID: 24732049     DOI: 10.1177/0272989X14526641

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  3 in total

Review 1.  Decision making in advanced heart failure: bench, bedside, practice, and policy.

Authors:  Daniel D Matlock; William C McGuire; Molly Magid; Larry Allen
Journal:  Heart Fail Rev       Date:  2017-09       Impact factor: 4.214

2.  Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.

Authors:  Maren H Harms; Rozanne C de Veer; Willem J Lammers; Christophe Corpechot; Douglas Thorburn; Harry L A Janssen; Keith D Lindor; Palak J Trivedi; Gideon M Hirschfield; Albert Pares; Annarosa Floreani; Marlyn J Mayo; Pietro Invernizzi; Pier Maria Battezzati; Frederik Nevens; Cyriel Y Ponsioen; Andrew L Mason; Kris V Kowdley; Bettina E Hansen; Henk R van Buuren; Adriaan J van der Meer
Journal:  Gut       Date:  2019-12-16       Impact factor: 31.793

3.  Testing for a Sweet Spot in Randomized Trials.

Authors:  Donald A Redelmeier; Deva Thiruchelvam; Robert J Tibshirani
Journal:  Med Decis Making       Date:  2021-08-11       Impact factor: 2.583

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.